Search

Find exactly what you’re looking for.
Search

Showing 1-18 of 18 results

PHILADELPHIA, (JUNE 10, 2024) – Michael Petrizzo and Julia Taylor, corporate attorneys with more than 50 years of combined experience, have joined Saul Ewing LLP as new partners. While Ms. Taylor is resident in the firm’s Washington, D.C. office, Mr. Petrizzo is resident in Philadelphia with a...

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

RIA: EB-5 Industry Experts Help You Prepare for New Changes, co-hosted by JTC Americas and Saul Ewing LLP.

What All Lawyers Need To Know About The State Of Immigration Law This white paper explores some of the biggest challenges you can expect to face when practicing immigration law. By ABOVE THE LAW AND EMBROKER

Controversial US Visa Draws Rich From China to India After Reset The EB-5 visa program coveted by many wealthy overseas investors is being revived after changes aimed at curbing abuses. By Blake Schmidt

CRE Investment Hot Streak Doused By Down Economy Economic forces at play across the globe, including the rising cost of capital and the threat of a U.S. recession have caused investors to think twice about how and where to place their money, with several leading indicators of deal volume slipping...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us